Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program

Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 observational databases (OBSER

(2018) Patrick B. Ryan et al.   DIABETES OBESITY & METABOLISM

SGLT-2 inhibitors and the risk of lower-limb amputation: Is this a class effect?

(2018) Charles Khouri et al.   DIABETES OBESITY & METABOLISM

Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes – A systematic review

(2018) Karin Rådholm et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study

(2018) Peter Ueda et al.   BMJ-British Medical Journal

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

(2017) Bruce Neal et al.   NEW ENGLAND JOURNAL OF MEDICINE

SGLT2 inhibitors and amputations in the US FDA Adverse Event Reporting System

(2017) Gian Paolo Fadini et al.   Lancet Diabetes & Endocrinology

Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2 Inhibitor

(2017) Jacob A. Udell et al.   CIRCULATION

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

(2015) Bernard Zinman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)—A randomized placebo-controlled trial

(2013) Bruce Neal et al.   AMERICAN HEART JOURNAL

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial

(2013) William T Cefalu et al.   LANCET